Literature DB >> 22008047

Pharmacogenomic characterization of US FDA-approved cytotoxic drugs.

Eric J Peters1, Alison Motsinger-Reif, Tammy M Havener, Lorraine Everitt, Nicholas E Hardison, Venita G Watson, Michael Wagner, Kristy L Richards, Mike A Province, Howard L McLeod.   

Abstract

AIMS: Individualization of cancer chemotherapy based on the patient's genetic makeup holds promise for reducing side effects and improving efficacy. However, the relative contribution of genetics to drug response is unknown. MATERIALS &
METHODS: In this study, we investigated the cytotoxic effect of 29 commonly prescribed chemotherapeutic agents from diverse drug classes on 125 lymphoblastoid cell lines derived from 14 extended families.
RESULTS: The results of this systematic study highlight the variable role that genetics plays in response to cytotoxic drugs, ranging from a heritability of <0.15 for gemcitabine to >0.60 for epirubicin.
CONCLUSION: Putative quantitative trait loci for cytotoxic response were identified, as well as drug class-specific signatures, which could indicate possible shared genetic mechanisms. In addition to the identification of putative quantitative trait locis, the results of this study inform the prioritization of chemotherapeutic drugs with a sizable genetic response component for future investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008047      PMCID: PMC3399590          DOI: 10.2217/pgs.11.92

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  13 in total

1.  Merlin--rapid analysis of dense genetic maps using sparse gene flow trees.

Authors:  Gonçalo R Abecasis; Stacey S Cherny; William O Cookson; Lon R Cardon
Journal:  Nat Genet       Date:  2001-12-03       Impact factor: 38.330

2.  Natural variation in human gene expression assessed in lymphoblastoid cells.

Authors:  Vivian G Cheung; Laura K Conlin; Teresa M Weber; Melissa Arcaro; Kuang-Yu Jen; Michael Morley; Richard S Spielman
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

Review 3.  A HapMap harvest of insights into the genetics of common disease.

Authors:  Teri A Manolio; Lisa D Brooks; Francis S Collins
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

4.  A first-generation physical map of the human genome.

Authors:  D Cohen; I Chumakov; J Weissenbach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

Review 5.  The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.

Authors:  Mark J Ratain; Antonius A Miller; Howard L McLeod; Alan P Venook; Merrill J Egorin; Richard L Schilsky
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

6.  Comprehensive human genetic maps: individual and sex-specific variation in recombination.

Authors:  K W Broman; J C Murray; V C Sheffield; R L White; J L Weber
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

7.  Genome-wide discovery of loci influencing chemotherapy cytotoxicity.

Authors:  James W Watters; Aldi Kraja; Melissa A Meucci; Michael A Province; Howard L McLeod
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-28       Impact factor: 11.205

Review 8.  Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity.

Authors:  J Todd Auman; Howard L McLeod
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

9.  Mapping genes that contribute to daunorubicin-induced cytotoxicity.

Authors:  Shiwei Duan; Wasim K Bleibel; Rong Stephanie Huang; Sunita J Shukla; Xiaolin Wu; Judith A Badner; M Eileen Dolan
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines.

Authors:  Edwin Choy; Roman Yelensky; Sasha Bonakdar; Robert M Plenge; Richa Saxena; Philip L De Jager; Stanley Y Shaw; Cara S Wolfish; Jacqueline M Slavik; Chris Cotsapas; Manuel Rivas; Emmanouil T Dermitzakis; Ellen Cahir-McFarland; Elliott Kieff; David Hafler; Mark J Daly; David Altshuler
Journal:  PLoS Genet       Date:  2008-11-28       Impact factor: 5.917

View more
  33 in total

1.  Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations.

Authors:  John Jack; Tammy M Havener; Howard L McLeod; Alison A Motsinger-Reif; Matthew Foster
Journal:  Pharmacogenomics       Date:  2015-08-28       Impact factor: 2.533

2.  Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance.

Authors:  J Jack; G W Small; C C Brown; T M Havener; H L McLeod; A A Motsinger-Reif; K L Richards
Journal:  Pharmacogenomics J       Date:  2017-12-05       Impact factor: 3.550

3.  Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines.

Authors:  Chad C Brown; Tammy M Havener; Marisa W Medina; John R Jack; Ronald M Krauss; Howard L McLeod; Alison A Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2014-02       Impact factor: 2.533

4.  Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.

Authors:  Uchenna O Njiaju; Eric R Gamazon; Lidija K Gorsic; Shannon M Delaney; Heather E Wheeler; Hae Kyung Im; M Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

5.  Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Lara Sánchez-Barroso; Maria Apellaniz-Ruiz; Gerardo Gutiérrez-Gutiérrez; María Santos; Juan M Roldán-Romero; Maria Curras; Laura Remacha; Bruna Calsina; Isabel Calvo; María Sereno; María Merino; Jesús García-Donas; Beatriz Castelo; Eva Guerra; Rocio Letón; Cristina Montero-Conde; Alberto Cascón; Lucía Inglada-Pérez; Mercedes Robledo; Cristina Rodríguez-Antona
Journal:  Oncologist       Date:  2018-11-23

Review 6.  Genomic architecture of pharmacological efficacy and adverse events.

Authors:  Aparna Chhibber; Deanna L Kroetz; Kelan G Tantisira; Michael McGeachie; Cheng Cheng; Robert Plenge; Eli Stahl; Wolfgang Sadee; Marylyn D Ritchie; Sarah A Pendergrass
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

7.  Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells.

Authors:  Hemant Kulkarni; Harald H H Göring; Joanne E Curran; Vincent Diego; Thomas D Dyer; Shelley Cole; Ken R Walder; Greg R Collier; John Blangero; Melanie A Carless
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-19       Impact factor: 3.333

Review 8.  Relating human genetic variation to variation in drug responses.

Authors:  Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Journal:  Trends Genet       Date:  2012-07-26       Impact factor: 11.639

Review 9.  Cancer pharmacogenomics: early promise, but concerted effort needed.

Authors:  Howard L McLeod
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

10.  A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.

Authors:  Chad C Brown; Tammy M Havener; Marisa W Medina; J Todd Auman; Lara M Mangravite; Ronald M Krauss; Howard L McLeod; Alison A Motsinger-Reif
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.